Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) an Israel-based pharmaceutical technology company, announced on Friday that it has added Dr Joseph V. Pergolizzi, Jr to its Scientific Advisory Board (SAB).
In the new role, Dr Pergolizzi is to concentrate on promoting pharmaceutical human product R&D and FDA filing, as outlined in his Advisory Board member services agreement.
Dr Pergolizzi has served in various C-level positions in private and public companies. He is a senior partner at Naples Anesthesia and Pain Associates and held the position of chief operating officer at NEMA Research Inc. He serves as a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics and a consultant to the National Pain Foundation board of directors. He is the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit. He has worked as a part-time adjunct assistant professor in the Department of Medicine at the Johns Hopkins University School of Medicine.
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA